SCHEMBL6323402

SCHEMBL6323402

CCC(NC(=O)OC(C)(C)C)C(OC)C(=O)N(C)[C@H](Cc1ccc2ccccc2c1)C(=O)N(C)[C@H](Cc1ccccc1)C(=O)NC

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.47
CTSB P07858 2/20 0.47
CTSK P43235 2/20 0.47
GHSR Q92847 2/20 0.42
KLK5 Q9Y337 2/20 0.40
FCER2 P06734 2/20 0.39
PTPN1 P18031 1/20 0.38
CTSL P07711 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRB2 P47870 1/20 0.37
ATM Q13315 1/20 0.36
ACE P12821 2/20 0.36
MME P08473 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366802 0.84 CTSS (0.60) CTSSCTSBCTSKGHSRFCER2
SCHEMBL7368069 0.83 GHSR (0.49) CTSSCTSBCTSKGHSRFCER2
SCHEMBL4428281 0.83 GHSR (0.49) CTSSCTSBCTSKGHSRFCER2
SCHEMBL6323403 0.83 CTSS (0.46) CTSSCTSBCTSKGHSRFCER2
SCHEMBL4423444 0.77 GHSR (0.63) CTSSCTSBCTSKGHSRFCER2
SCHEMBL4423447 0.77 GHSR (0.63) CTSSCTSBCTSKGHSRFCER2
SCHEMBL7160870 0.77 CTSB (0.42) CTSSCTSBCTSKGHSRFCER2
SCHEMBL6317980 0.77 GHSR (0.43) CTSSCTSBCTSKGHSRFCER2
SCHEMBL8717973 0.77 GHSR (0.43) CTSSCTSBCTSKGHSRFCER2
SCHEMBL3273825 0.75 GHSR (0.47) CTSSCTSBCTSKGHSRPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 CTSS 2319/4885CTSB 967/4885CTSK 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.